Alpha Clinical Research Centers LLC

1. Regeneron Pharmaceuticals, Inc. $1,086,378 412 payments
2. Hexal AG $170,056 63 payments
3. Pfizer Inc. $108,877 6 payments
4. Sanofi US Services Inc. $78,321 27 payments
5. BioNTech SE $42,712 18 payments
6. AstraZeneca UK Limited $26,657 3 payments
7. Stemline Therapeutics Inc. $12,694 8 payments
8. BeiGene, Ltd. $11,920 6 payments
9. BeOne Medicines Ltd. $10,150 3 payments
10. MacroGenics, Inc. $7,977 3 payments

1. A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% $819,403 332 payments
2. A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels $132,802 48 payments
3. A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC $130,839 31 payments
4. Cgme751a12101 $79,636 40 payments
5. A Phase 1/2, dose escalation and expansion study of the safety, tolerability, and anti-tumor activity of BND-22 administered alone and in combination with pembrolizumab or with cetuximab in patients with advanced solid tumors $78,321 27 payments
6. Cgme751a12301 $64,626 18 payments
7. Bnt327 $37,583 11 payments
8. An Interventional Phase 3 Doubleblind Randomized Study to Evaluate Efficacy and Safety of Pf08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Locally Advanced Or Metastatic Nonsmall Cell Lung Cancer $28,457 1 payment
9. Cgme751a12302 $25,794 5 payments
10. An Interventional Openlabel Randomized Multicenter Phase 3 Study of Pf07220060 Plus Letrozole Compared to Cdk46 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor Hrpositive Her2negative Advancedmetastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment for Advancedmetastatic Disease Fourlight3 $25,074 2 payments

1. Other $7,977 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.